Toxin News and Research

RSS

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

New findings on snake venom toxin hold promise for developing heart disease, cancer therapies

Researchers seeking to learn more about stroke by studying how the body responds to toxins in snake venom are this week releasing new findings that they hope will aid in the development of therapies for heart disease and, surprisingly, cancer. The Japanese team is reporting in a Journal of Biological Chemistry "Paper of the Week" that they are optimistic that inhibiting a protein found on the surface of blood cells known as platelets may combat both irregular blood clotting and the spread of certain cancers throughout the body.

30 Jul 2010

FDA clears IL's new point-of-care total bilirubin assay

Instrumentation Laboratory (IL) today announced that it has received clearance from the US Food and Drug Administration (FDA) to market the first-ever, rapid point-of-care, lab-quality blood test for measuring total bilirubin (tBili) in newborns.

28 Jul 2010

New study links facial expressions with written language

Your facial expression may tell the world what you are thinking or feeling. But it also affects your ability to understand written language related to emotions, according to research published in the July issue of Psychological Science, a journal of the Association for Psychological Science.

20 Jul 2010

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full scale production by Lonza under a separate agreement announced in 2009.

16 Jul 2010

Microbiologists work to decrease mold growth in flooded homes through improved prevention, cleanup

A team of microbiologists at the U.S. Department of Energy's Savannah River National Laboratory is working with Tuskegee University and Mississippi State University to decrease mold growth in flooded homes through improved prevention and cleanup.

15 Jul 2010

FDA clears Meridian Bioscience's new illumigene C. difficile molecular amplification assay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its new molecular amplification assay, illumigene™ C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon.

14 Jul 2010

New treatments to alleviate symptoms of muscular dystrophy, depression and dementia

Scientists researching a toxin extracted from the venom of the honey bee have used this to inform the design of new treatments to alleviate the symptoms of conditions such as muscular dystrophy, depression and dementia.

12 Jul 2010

Federal food safety agencies commended for supporting Food Safety Working Group

Agriculture Secretary Tom Vilsack and Secretary of Health and Human Services Kathleen Sebelius today commended federal food safety agencies for their accomplishments supporting the charge of President Obama's Food Safety Working Group, which advises the President on how to upgrade the U.S. food safety system for the 21st century.

12 Jul 2010

Allergan receives UK MHRA authorisation of BOTOX for prophylaxis of headache in chronic migraine

Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). This is the first licence worldwide of BOTOX® for this indication, and is also the first prophylactic (preventative) treatment to receive a specific licence for patients with chronic migraine.

9 Jul 2010

Department of Agriculture asks consumers to discard Milky Way Farm's hard cheddar cheese

The Department of Agriculture today advised consumers who purchased aged hard cheddar cheese made with raw milk from Milky Way Farm in Troy, Bradford County, to discard the product immediately because of potential bacterial contamination. The Bureau of Food Safety has identified 20 pounds of raw milk cheddar cheese that entered the consumer market.

9 Jul 2010

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it continues to make solid progress in its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine development program. The Company has recently demonstrated that its lyophilized rPA vaccine candidate is structurally stable and potent at various temperatures up to and including 70 degrees centigrade.

9 Jul 2010

Molecular Templates enters into oncology drug discovery and translation research agreement with ImClone

Molecular Templates announced today that it has entered into a collaborative oncology drug discovery and translation research agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.

7 Jul 2010

Mice study may provide new insight on human pregnancies

The concept of pregnancy makes no sense-at least not from an immunological point of view. After all, a fetus, carrying half of its father's genome, is biologically distinct from its mother. The fetus is thus made of cells and tissues that are very much not "self"-and not-self is precisely what the immune system is meant to search out and destroy.

2 Jul 2010

Researchers study mechanism of human brain

Because of its intricate organization, figuring out the wiring diagram that explains how the billions of neurons in the brain are connected, and determining how they work together, remains a formidable task.

29 Jun 2010

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax™, the Company's vaccine against ricin toxin.

28 Jun 2010

Overview of scientific research on medical technology to combat anthrax threat

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

25 Jun 2010

Increasing the amount of preservatives may reduce food poisoning

In response to consumer demand for more natural food, the food industry has reduced the amount of preservatives in food over recent years. A common preservative is acetic acid, which is used to stop bacterial growth in dressings, sauces, cheese and pickles.

25 Jun 2010

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2010.

24 Jun 2010

Toxin News and Research

Allergan second-quarter diluted EPS increases to $0.78

Xeomin receives FDA approval for treatment of cervical dystonia

New findings on snake venom toxin hold promise for developing heart disease, cancer therapies

FDA clears IL's new point-of-care total bilirubin assay

New study links facial expressions with written language

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

Microbiologists work to decrease mold growth in flooded homes through improved prevention, cleanup

FDA clears Meridian Bioscience's new illumigene C. difficile molecular amplification assay

New treatments to alleviate symptoms of muscular dystrophy, depression and dementia

Federal food safety agencies commended for supporting Food Safety Working Group

Allergan receives UK MHRA authorisation of BOTOX for prophylaxis of headache in chronic migraine

Department of Agriculture asks consumers to discard Milky Way Farm's hard cheddar cheese

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

Molecular Templates enters into oncology drug discovery and translation research agreement with ImClone

Mice study may provide new insight on human pregnancies

Researchers study mechanism of human brain

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Overview of scientific research on medical technology to combat anthrax threat

Increasing the amount of preservatives may reduce food poisoning

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News